Latest news with #Juan
Fox News
2 days ago
- Business
- Fox News
Airline celebrates Pride month with 'all-2SLGBTQIA flight'
Air Canada celebrated its "first all-2SLGBTQIA+" in posts on social media Monday. "Our first all-2SLGBTQIA+ flight was a heartfelt celebration reflecting our unwavering commitment to inclusivity and equality, in the air and on the ground," Air Canada said in a post on X, accompanied by a video. 2SLGBTQIA+ stands for two-spirit, lesbian, gay, bisexual, transgender, queer or questioning, intersex and asexual. The plus sign is meant to show the various ways people express themselves under the 2SLGBTQIA+ name. "I thought it was a great initiative for the whole community," Jean-François, identified as a station attendant, said in the video. "It's somewhat of a thrill being on this flight today." Another station attendant, René JR, felt similarly. "I'm here to support my daughter," he said. "One of my four children is part of this community. When I saw there was an opportunity to support her even more, I signed up for it right away." Juan, a first officer, also featured in the Air Canada video, said, "What this means today is that this is a really special moment. It has to do with visibility, with the possibility of telling everyone that we truly feel welcome and accepted for who we are." Some reactions to the post on X, however, were not as positive. Curtis Houck, managing editor of NewsBusters, posted on X, "This is a parody, right?" Canadian blogger Mark Slapinski said, "Air Canada has gone FULLY WOKE. Raise your hand if you'll never fly on their airlines AGAIN." Fox News Digital reached out to Air Canada for comment, but did not immediately receive a response.
Straits Times
28-05-2025
- Sport
- Straits Times
Chelsea and Betis fans clash before Conference League final
WROCLAW, Poland - Fans of Chelsea and Real Betis have clashed ahead of Wednesday's Conference League final in Polish host city Wroclaw, authorities said, warning they would clamp down hard on violence. Footage on social media showed fans in the city centre hurling chairs at each other and taking part in running battles on Tuesday evening. Polish police said they were attempting to identify fans involved in one incident and had detained a Spanish citizen after a scuffle on Tuesday night. A further three Spaniards were detained in the early hours of Wednesday after they took down UEFA Conference League Final flags. Last week's Europa League final between Manchester United and Tottenham Hotspur was also marred by clashes between supporters ahead of the match in Bilbao. "Zero tolerance for violence on our streets!," Polish Prime Minister Donald Tusk wrote on X. "I thank the police for their decisive actions against the hooligans in Chelsea and Betis shirts in Wroclaw. We warn you: if necessary, the police will be even more ruthless today!" 'WE'RE NOT SCARED' Polish police said everyone could feel safe thanks to a large police presence saturating certain areas. Chelsea, twice Champions League winners and six times English top-flight champions, arrive at the final having secured fourth place in the Premier League on Sunday, giving them Champions League football next season. Real Betis supporters, meanwhile, are revelling in reaching a European final for the first time in the club's history and the chance to overshadow local rivals Sevilla with their own chapter of continental success. Hours before the game on Wednesday afternoon, under steady rain, most fans were brushing off the violence. "There is always someone bad in a crowd of 50,000 people," said Betis supporter Juan in Wroclaw's old town square. "We are loving every second of this , we're going to celebrate afterwards, and we hope Chelsea fans will cry." Another Betis fan, Maria, added: "We're not scared, we're very happy. Most of us just want to enjoy the football and the match." REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Time of India
27-05-2025
- Entertainment
- Time of India
New on Netflix This Week (May 26–31): From Dept. Q to Mad Unicorn, 9 fresh binge bombs you'll regret sleeping on
New on Netflix This Week (May 26–31): Brace yourselves, couch potatoes and streaming savants. Netflix just restocked the shelves of your emotional refrigerator and the menu? Juicy, mysterious, hilarious, deadly, and oh-so bingeable. This week's lineup is hotter than your ex's Instagram after a breakup. Here's everything dropping from May 26 to 31 that you'll want to cancel plans for. Ready, set, obsess. 1. Cold Case: The Tylenol Murders (May 26) Plot twist: The pill that gave you headache relief in the '80s? Yeah, it gave Chicago a massive case of trust issues. At least seven people died after taking cyanide-laced Tylenol, and the world hasn't looked at a medicine cabinet the same way since. From the creators behind Conversations with a Killer and Shadow of Truth, this deep dive questions whether the real killer was ever found… or whether a sinister cover-up is hiding in plain sight. 2. Mike Birbiglia: The Good Life (May 26) Ah, Mike's back, and this time, he's unpacking the chaotic joys of marriage and parenting. Why do kids' birthday parties require a survival kit now?! Equal parts laugh-out-loud funny and sneakily heartfelt, Birbiglia drops truth bombs with perfect timing and just the right dash of dad energy. 3. F1: The Academy (May 28) Move over, boys. The grid's about to get a makeover. Fifteen fierce, focused women are taking the wheel and proving they belong in the high-octane, testosterone-flooded world of Formula 1. Expect fast cars, faster comebacks, and a whole lot of feminist fire. 4. Losmen Bu Broto: The Series (May 29) Tarjo's tired of being invisible in his own family's inn. Cue: ambition, betrayal, and a forbidden romance with a married guest (we see you, plot twist). Set in Yogyakarta, this series is dripping in cultural charm and messy family drama. Watch it when you're craving something slow-burning and full of secrets. 5. Dept. Q (May 29) DCI Carl Morck is your classic tortured genius: brilliant, bitter, and basically exiled to a basement after a botched operation. But when a long-dead cold case suddenly warms up, Carl assembles a ragtag team to take down corruption from the shadows. Think Sherlock meets Luther with less tea and more trauma. 6. Mad Unicorn (May 29) Cue your next entrepreneurial obsession. When one underdog launches a courier startup, the success isn't just surprising but rather threatening. Enemies multiply. Tensions rise. And somewhere between ambition and survival, lines get crossed. 7. A Widow's Game (May 30) Valencia, 2017. A man is found stabbed seven times in a parking lot. It screams passion crime, but what doesn't scream is his young, sweet widow Maje being the prime suspect. But darling, looks deceive. This one's a layered slow-burn thriller that'll keep you shouting 'WHAT?!' every ten minutes. 8. The Heart Knows (May 30) Warning: You may cry. Juan receives a heart transplant from a kind man named Pedro. Cue the plot twist - Juan meets Pedro's widow, Valeria, and falls in love without telling her the whole heart connection thing. Oh, and he's trying to save Pedro's neighbourhood too. 9. Lost in Starlight (May 30) 2050 Seoul: Aspiring astronaut Nan-young is grounded. Musician Jay is stuck in nostalgia. They meet, they fall, they dream of space and each other. But when she finally gets her shot at Mars, love and ambition clash in the most celestial way possible. Watch it when you want love that spans galaxies (and doesn't ghost you halfway to Mars). This week on Netflix, the drama is real, the laughs are loud, and your weekend plans just got booked solid. Pass the snacks and clear your calendar - we've got 9 reasons to never leave your couch.
Yahoo
21-05-2025
- Business
- Yahoo
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential
We recently published an article titled . Perspective Therapeutics, Inc. (NYSE:CATX) was one of the stocks that was covered in that article. Wall Street analysts believe CATX has a 460% upside potential over the next 12 months. A surgeon wearing a medical mask, examining a cancer patient in a surgical facility. Perspective Therapeutics, Inc. (NYSE:CATX), a biotechnology company specializing in precision-targeted alpha therapies (TAT) for cancer treatment, has steadily carved a niche in the realm of oncology. Initially founded in 1998 as Isoray, Inc., the company underwent a transformative rebranding in February 2023, following its merger with Viewpoint Molecular Targeting, Inc. This strategic move has strengthened its positioning in the competitive biotech landscape, enabling it to focus on developing innovative solutions for some of the most challenging cancer types. The company's primary drug candidates demonstrate its commitment to precision medicine. VMT-α-NET, currently in Phase 1/2a clinical trials, targets neuroendocrine tumors with precision, offering hope for patients battling these often difficult-to-treat malignancies. Additionally, PSV359 aims to address fibroblast activation protein alpha, further showcasing Perspective Therapeutics' diverse therapeutic approach. By employing an integrated theranostic model (combining diagnostics and therapeutics), the company effectively delivers targeted radiation to cancer cells while minimizing harm to surrounding healthy tissue. This innovative method exemplifies its dedication to enhancing treatment efficacy and patient outcomes. Perspective Therapeutics' strategic collaborations are the cornerstone of it's business model. CATX's partnership with Bristol Myers Squibb to evaluate the safety and tolerability of VMT01, used alongside nivolumab for melanoma patients, highlights the company's focus on leveraging leading-edge research to advance its clinical programs. Furthermore, its manufacturing and supply capabilities, developed across facilities in Iowa and New Jersey, underpin both ongoing clinical trials and potential commercial-scale operations. The organization also maintains global development rights for its promising candidates, ensuring flexibility and control throughout its pipeline. Perspective Therapeutics works closely with prominent academic institutions such as the University of Iowa and Mayo Clinic, fostering innovation and scientific rigor in its research. Leveraging partnerships, advanced technology, and strategic growth initiatives, the company is poised to make significant strides in oncology. A recent filing reveals that in March of 2025, Graham Juan, Chief Financial Officer of Perspective Therapeutics, Inc. (NYSE:CATX), reportedly made a notable investment in the company's common stock. The report shows that Mr. Juan acquired 33,333 shares at a weighted average price of approximately $2.25 per share, totaling $74,945. The purchase comes as the stock hovers near its 52-week low, having fallen over 83% in the past year. Analysts on Wall Street have taken notice, with 93% expressing optimism regarding the stock's future performance. As of May 13, 2025, the consensus among analysts places the twelve-month projected share price at $14.32, signifying an impressive upside potential of 460.47%. This outlook reflects growing confidence in Perspective Therapeutics' ability to deliver transformative treatments to patients worldwide. Overall, Perspective Therapeutics, Inc. (NYSE:CATX) ranks 5th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of CATX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CATX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential
We recently published an article titled . Perspective Therapeutics, Inc. (NYSE:CATX) was one of the stocks that was covered in that article. Wall Street analysts believe CATX has a 460% upside potential over the next 12 months. A surgeon wearing a medical mask, examining a cancer patient in a surgical facility. Perspective Therapeutics, Inc. (NYSE:CATX), a biotechnology company specializing in precision-targeted alpha therapies (TAT) for cancer treatment, has steadily carved a niche in the realm of oncology. Initially founded in 1998 as Isoray, Inc., the company underwent a transformative rebranding in February 2023, following its merger with Viewpoint Molecular Targeting, Inc. This strategic move has strengthened its positioning in the competitive biotech landscape, enabling it to focus on developing innovative solutions for some of the most challenging cancer types. The company's primary drug candidates demonstrate its commitment to precision medicine. VMT-α-NET, currently in Phase 1/2a clinical trials, targets neuroendocrine tumors with precision, offering hope for patients battling these often difficult-to-treat malignancies. Additionally, PSV359 aims to address fibroblast activation protein alpha, further showcasing Perspective Therapeutics' diverse therapeutic approach. By employing an integrated theranostic model (combining diagnostics and therapeutics), the company effectively delivers targeted radiation to cancer cells while minimizing harm to surrounding healthy tissue. This innovative method exemplifies its dedication to enhancing treatment efficacy and patient outcomes. Perspective Therapeutics' strategic collaborations are the cornerstone of it's business model. CATX's partnership with Bristol Myers Squibb to evaluate the safety and tolerability of VMT01, used alongside nivolumab for melanoma patients, highlights the company's focus on leveraging leading-edge research to advance its clinical programs. Furthermore, its manufacturing and supply capabilities, developed across facilities in Iowa and New Jersey, underpin both ongoing clinical trials and potential commercial-scale operations. The organization also maintains global development rights for its promising candidates, ensuring flexibility and control throughout its pipeline. Perspective Therapeutics works closely with prominent academic institutions such as the University of Iowa and Mayo Clinic, fostering innovation and scientific rigor in its research. Leveraging partnerships, advanced technology, and strategic growth initiatives, the company is poised to make significant strides in oncology. A recent filing reveals that in March of 2025, Graham Juan, Chief Financial Officer of Perspective Therapeutics, Inc. (NYSE:CATX), reportedly made a notable investment in the company's common stock. The report shows that Mr. Juan acquired 33,333 shares at a weighted average price of approximately $2.25 per share, totaling $74,945. The purchase comes as the stock hovers near its 52-week low, having fallen over 83% in the past year. Analysts on Wall Street have taken notice, with 93% expressing optimism regarding the stock's future performance. As of May 13, 2025, the consensus among analysts places the twelve-month projected share price at $14.32, signifying an impressive upside potential of 460.47%. This outlook reflects growing confidence in Perspective Therapeutics' ability to deliver transformative treatments to patients worldwide. Overall, Perspective Therapeutics, Inc. (NYSE:CATX) ranks 5th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of CATX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CATX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
